ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

DL4

Its studies are led by Sun Pharmaceutical Industries.

Furthest: phase 1, since May 28, 20251 company-led study, 1 open or runningNext primary completion: Aug 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sun Pharmaceutical Industries11 open or runningphase 1since May 28, 2025May 28, 2025Aug 2028phase 1 · NCT07042100

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First study: phase 1 study in Advanced Solid TumorsFirst studyNCT07042100 · 177 planned · United States, Australia, India

Ahead

  1. Aug 2028Primary completion: phase 1 study in Advanced Solid TumorsNCT07042100

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07042100Advanced Solid Tumors · United States, Australia, India1RecruitingAug 2028177

How it is read

Names in the registry

  • “DL4”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.